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Abstract
Background: Cell lines are often poorly characterized from a genetic point of view, reducing their
usefulness as tumor models. Our purpose was to assess the genetic background of eight commonly
used human thyroid carcinoma models and to compare the findings with those reported for
primary tumors of the gland.
Methods: We used chromosome banding analysis and comparative genomic hybridization to
profile eight non-medullary thyroid carcinoma cell lines of papillary (TPC-1, FB2, K1 and B-CPAP),
follicular (XTC-1) or anaplastic origin (8505C, C643 and HTH74). To assess the representativeness
of the findings, we additionally performed a thorough review of cytogenetic (n = 125) and DNA
copy number information (n = 270) available in the literature on clinical samples of thyroid
carcinoma.
Results: The detailed characterization of chromosomal markers specific for each cell line revealed
two cases of mistaken identities: FB2 was shown to derive from TPC-1 cells, whereas K1 cells have
their origin in cell line GLAG-66. All cellular models displayed genomic aberrations of varying
complexity, and recurrent gains at 5p, 5q, 8q, and 20q (6/7 cell lines) and losses at 8p, 13q, 18q, and
Xp (4/7 cell lines) were seen. Importantly, the genomic profiles were compatible with those of the
respective primary tumors, as seen in the meta-analysis of the existing literature data.
Conclusion:  We provide the genomic background of seven independent thyroid carcinoma
models representative of the clinical tumors of the corresponding histotypes, and highlight regions
of recurrent aberrations that may guide future studies aimed at identifying target genes. Our
findings further support the importance of routinely performing cytogenetic studies on cell lines,
to detect cross-contamination mishaps such as those identified here.
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Background
Thyroid cancer represents the most frequent endocrine
malignancy in humans, ranging from the more differenti-
ated carcinomas with papillary (80–90% of all occur-
rences) or follicular (5–10%) histotypes, to the rare and
clinically more aggressive anaplastic carcinomas (2–
5%)[1]. Many of the genetic events leading to the onco-
genic and metastatic potential of these distinct malignan-
cies have already been identified [2]. Papillary thyroid
carcinomas (PTC) frequently harbor activating rearrange-
ments of RET (8–33%) or NTRK1 (5–15%) genes, both
coding for receptor tyrosine kinases that exert control over
a wide range of transcription factors [3]. Some PTC may
display, instead, mutually exclusive point mutations in
RAS (0–21%) or BRAF (29–83%), leading to the constitu-
tive activation of the RAS-RAF-MEK-ERK signaling path-
way [4]. Follicular thyroid carcinomas (FTC), on the other
hand, are known to harbor PAX8-PPAR  gene fusions (25–
60% of the cases) and also mutations in RAS (21–50%)
[4]. Undifferentiated thyroid carcinomas (UTC) may dis-
play RET rearrangements (less than 10%) or point muta-
tions in RAS  (20–60%) or BRAF  (0–63%), as well as
mutations in TP53 (up to 60%), which is in accordance
with the hypothesis that most UTC originate from well-
differentiated lesions through the multi-step accumula-
tion of genetic aberrations [2,4]. Deregulation of the
phosphatidylinositol 3-kinase (PI3K)/Akt pathway
through amplification or activating mutations at the cata-
lytic subunit of PI3K (PIK3CA, 12–23%), or inactivating
mutations of key inhibitors such as PTEN (up to 16%),
also plays a relevant role in UTC etiology [5].
The molecular mechanisms behind a considerable pro-
portion of thyroid carcinomas remain nevertheless
unclear, and extensive effort has been placed in creating in
vitro and in vivo models of thyroid carcinogenesis. Several
cell lines derived from PTC, FTC, and UTC carcinomas
have been established and are widely used to evaluate
novel oncogenic events or molecular markers with diag-
nostic, prognostic and/or therapeutic potential. The
genetic content of many of these cell lines, however, is
poorly or only partially characterized, making it difficult
to assess the pathogenetic role of specific gene rearrange-
ments in the absence of a general picture of the genomic
background of each cell line.
To contribute to the genetic characterization of the in vitro
models of non-medullary thyroid carcinogenesis, we per-
formed chromosome banding analysis and chromosomal
comparative genomic hybridization (CGH) on eight
human thyroid carcinoma cell lines originating from pap-
illary carcinomas (TPC-1, FB2, K1, and B-CPAP), follicular
carcinoma (XTC-1) or undifferentiated carcinomas
(C643, 8505C, and HTH74). We additionally review the
karyotypic and CGH information available in the litera-
ture for these three thyroid carcinoma histotypes, in order
to assess the primary tumor representativeness of these
cell lines.
Methods
Cell lines and culture conditions
A total of eight human thyroid carcinoma cell lines, orig-
inally thought to derive from distinct patients, were
assessed in the present study (Table 1). All cell lines were
maintained in RPMI medium with Glutamax (GIBCO
BRL – Invitrogen Corporation, Carlsbad, CA) supple-
mented with 10% fetal bovine serum (FBS) and antibiot-
ics, except for K1 which was cultured in Dulbecco's
modified Eagle's medium (GIBCO BRL – Invitrogen Cor-
poration, Carlsbad, CL) supplemented with 10% FBS and
antibiotics. Cells were cultured as monolayer in a humid-
ified atmosphere (5% carbon dioxide) at 37°C.
Chromosome banding analysis
Upon attaining optimal cellular density, cultures were
harvested and cells divided into two tubes. One tube was
processed for cytogenetic analysis, and metaphases were
GTG-banded according to standard procedures. The sec-
ond tube was used for DNA extraction. Clonality criteria
and karyotype description followed the International Sys-
tem for Human Cytogenetic Nomenclature (ISCN) 2005
[6].
Comparative genomic hybridization
Chromosomal CGH was performed as previously
described [7]. Briefly, test (cell lines) and reference (periph-
eral blood lymphocytes from healthy donors) DNA was
extracted using standard methods and labeled in nick trans-
lation reactions using SpectrumGreen- and SpectrumRed-
conjugated nucleotides (Vysis, Downers Grove, IL). The
same amount of differentially labeled cell line and refer-
ence DNA (1 μg) was then mixed with Cot-1 DNA (30 μg)
and hybridized onto commercially available, normal met-
aphase slides (Vysis, Downers Grove, IL). Hybridization
took place for 2–3 days at 37°C in a moist chamber, after
which excess probe was washed off and DAPI counterstain
was applied. Analysis was performed using a Zeiss Axioplan
fluorescence microscope (Zeiss, Oberkochen, Germany)
and a CytoVision system version 3.0 (Applied Imaging,
Santa Clara, CA). Scoring was based on dynamic standard
reference intervals generated based on data from 10 normal
versus normal hybridizations. Aberrations were scored
whenever the case profile and the standard reference profile
at 99% confidence did not overlap. Amplifications were
scored whenever the 99% confidence interval for a given
sample crossed the 1.75 threshold. Description of CGH
copy number changes followed the recommendations of
the ISCN 2005 [6].
Literature review
Karyotypic information for non-medullary thyroid carci-
noma samples was obtained from Mitelman database ofBMC Cancer 2008, 8:371 http://www.biomedcentral.com/1471-2407/8/371
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chromosomal aberrations in cancer [8]. Cases were subdi-
vided according to the three major histotypes (papillary,
follicular and anaplastic) and the modal number, the total
number of chromosome aberrations, and all breakpoints
in each sample were annotated. Chromosomal CGH
information was obtained from thyroid carcinoma publi-
cations listed in the Progenetix database [9], and copy
number diagrams were generated for each of the three his-
totypes.
Fluorescence in situ hybridization
Locus-specific probes targeting chromosomal regions
5p15 and 5q33-34 were applied to C643 and HTH74 met-
aphase spreads in order to clarify the origin of several
chromosomal markers. Sample processing, hybridization,
and analysis were performed according to standard proto-
cols. Briefly, the same nuclear suspensions prepared for
cytogenetic studies were dropped onto glass slides, air
dried and pre-treated in 2 × SSC/0.5% Igepal (Sigma-
Aldrich, Steinheim, Germany) at 37°C for 30 minutes,
after which slides were dehydrated in a series of ethanol.
A SpectrumOrange labeled CSF1R probe (5q33-34) and a
SpectrumGreen labeled D5S23/D5S721 probe (5p15.2)
were applied to both cell line samples (Vysis, Downers
Grove, IL). Slides were placed in a Hybrite denaturation/
hybridization system (Vysis, Downers Grove, IL) and co-
denatured at 75°C for 3 minutes. Hybridization took
place for 18 h at 37°C, followed by post-hybridization
washes in 0.4 × SSC/0.3% Igepal at 72°C for 2 minutes
and 2 × SSC/0.1% Igepal at room temperature for 1
minute. Slides were counterstained with DAPI (Vector
Laboratories, Burlingame, CA).
Results
A detailed description of the cytogenetic and molecular
cytogenetic findings obtained in the eight cell lines is pre-
sented in Table 2, and representative karyograms are sup-
plied as supplementary files (Additional files 1, 2, 3, 4, 5,
6, 7, 8). Interestingly, the cytogenetic features shared by
cell lines TPC-1 and FB2 show that the latter is derived
from the former through cross-contamination (Addi-
tional files 9, 10), thus reducing to seven the number of
independent cell lines studied. To facilitate visual compar-
isons between findings on different cell lines and to inte-
grate these data with the available genetic information on
primary tumor samples, diagrams integrating G-banding
and CGH information were generated for the three
assessed thyroid tumor histotypes (Figures 1, 2, 3).
Table 1: Tumor origin and source of the eight thyroid cell lines analyzed in this study
Cell line Tumor origin Gender Source References*
TPC-1 Papillary carcinoma Female Prof Dumont JE; Prof Mareel M;
Laboratory of Experimental Cancerology, Ghent 
University Hospital,
Ghent, Belgium
Tanaka et al. 1987 [10]
Jossart et al. 1995 [15]
Miura et al. 2003 [20]
van Staveren et al. 2007 [21]
FB2
(TPC-1)
Papillary carcinoma Female Prof. Santoro M;
Centro di Endocrinologia ed Oncologia Sperimentale,
Napoly, Italy
Basolo et al. 2002 [16]
K1
(GLAG-66)
Papillary carcinoma Male Prof. Wynford-Thomas D;
Department of Pathology, University of Wales College 
of Medicine,
Cardiff, U.K.
Antonini et al. 1993 [19]
Challeton et al. 1997 [18]
B-CPAP Papillary carcinoma Female Prof Mareel M;
Laboratory of Experimental Cancerology, Ghent 
University Hospital,
Ghent, Belgium
Paulin et al. 1992 [29]
Corso et al. 2002 [22]
Dettori et al. 2004 [23]
van Staveren et al. 2007 [21]
XTC-1 Follicular carcinoma (Hürthle cell) Female Prof. Savagner F;
Laboratoire de Biochimie et Biologie Moleculaire, 
Faculte de Medecine,
Angers, France
Zielke et al. 1998 [30]
HTH74 Undifferentiated carcinoma Female Prof Mareel M;
Laboratory of Experimental Cancerology, Ghent 
University Hospital,
Ghent, Belgium
Heldin et al. 1991 [31]
Lee et al. 2007 [24]
C643 Undifferentiated carcinoma Male Prof Mareel M;
Laboratory of Experimental Cancerology, Ghent 
University Hospital,
Ghent, Belgium
Mark et al. 1987 [32]
Lee et al. 2007 [24]
8505C Undifferentiated carcinoma Female Prof Mareel M;
Laboratory of Experimental Cancerology, Ghent 
University Hospital,
Ghent, Belgium
Ito et al. 1992 [33]
van Staveren et al. 2007 [21]
Lee et al. 2007 [24]
* Only papers detailing the establishment (references in bold) or providing relevant genetic information for each cell line are indicated.BMC Cancer 2008, 8:371 http://www.biomedcentral.com/1471-2407/8/371
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Cell line overview
All cell lines displayed numerical and structural aberra-
tions of varying complexity, some of which could not be
completely identified by classical cytogenetic analysis.
Isochromosomes 5p (3 cell lines) and 8q (2 cell lines)
were seen recurrently, whereas similar breakpoints were
seen by chromosome banding at 1p36 (3 events), 5q13 (3
events), and 3p21, 7q31, 8p22, 9p23, and 10p11 (2
events each). Interestingly, distinct cytogenetic aberra-
tions resulted in identical net gain and/or loss of genomic
material at several chromosomal regions, as seen by CGH.
In particular, gains at 5p, 5q, 8q, and 20q were seen in 6/
Table 2: Cytogenetic and chromosomal CGH findings in seven unique thyroid cell lines
Cell line Karyotype CGH
TPC-1 49,XX,der(1)t(1;10;21)(1pter→1q31::21q21→21qter), 
+der(1)t(1;3)(p13;p21),der(3)t(3;9)(p11;q22), 
del(7)(q22q31),+i(8)(q10),der(10)t(1;10;21) 
(10q11.2→10pter::1q31→1qter),+der(10)inv(10) 
(q11.2q21)t(3;10)(q25;p11),der(21)t(1;10;21) 
(21pter→21q21::10q21.2→10q11.2::10q21.
2→10qter)[25]
rev ish enh(1)(q),dim(3)(p12p21),enh(3)(q24q29), 
dim(7)(q21q31),amp(8)(q),enh(9)(q22q34),enh(10)(q)
K1
(GLAG-66)
87~93,XXYY,der(1)t(1;9;9)(9pter→9p11::1p11→1q44
::9p12→9pter)x2,i(5)(p10),i(5)(q10),der(7)t(1;7) 
(p31;q31),der(8)t(8;9)(p22;p23)x2,+der(8)t(1;8) 
(p11;q11),del(9)(p11)x2,del(9)(p12)x2,-13,-14,-16, -
17,der(18)t(17;18)(q21;q12)x2,+20 [cp25]
rev ish enh(5),dim(8)(p21p23),enh(8)(q), 
amp(9)(p22p24),dim(14)(q),dim(16),dim(17)(p13), 
enh(17)(q21q25),dim(18)(q12q23),enh(20)
B-CPAP 70~74,XX,-X,der(1)t(1;1)(p12;p21),der(5)t(5;9) 
(q11;q12), +dic(5;13)(p12;q12),+i(5)(p10),-7, 
der(8)t(5;8)(q13;p21),der(9)t(9;9)(p23;q31), 
der(10)t(1;10)(q25;p11),der(10)t(1;10)(q11.2;p11.2) 
del(1)(q21q32),+11,+dic(12;20)(p11;p11),-13,+15, 
add(16)(q22),der(17)inv(17)(p13q11)inv(17)(q11q23),
+20,+20,der(20)t(7;20)(p11;p11),-22 [cp25]
rev ish dim(X),enh(1)(p21p36),dim(1)(q21q31), 
enh(2)(p11p12),enh(5)(p12p15),enh(5)(q13q35), 
dim(7)(q),dim(8)(p22p23),dim(9)(p),enh(9)(q32q33), 
dim(10)(p),enh(11),enh(12)(q12q24),dim(13)(q), 
enh(15)(q),dim(16)(q11q22),enh(17)(q21q25),amp(20),dim(22)(q)
XTC-1 51~58,XX,add(1)(p36),+5,+7,+7,+der(8;12)(q10;q10)x
2,dup(10)(q22q24),add(12)(q14),del(12)(q13),+16, 
+del(18)(q11),+19,+19,der(19)t(1;19)(q21;p13) 
del(19)(q13)x2,+20,add(20)(p11)x2 [cp25]
rev ish enh(1)(q),enh(5),amp(7),amp(8)(q), 
enh(9)(q12q31),enh(9)(q33q34),enh(12)(q11q21), 
amp(12)(q11q15),dim(14)(q32),enh(16),enh(18)(p), 
enh(19)(p13q13),enh(20)(q),amp(20)(q13)
HTH74 57~60,X,der(X)t(X;17)(p11;q12),+add(1)(p13), 
der(1)t(X;1)(p21;p36),der(2)t(2;20)(q21;q13),t(3;8) 
(p21;q22)x2,dup(5)(q22q35)x2,+i(5)(p10)x2,+7,+7, 
+8,+8,+10,+del(11)(q13)x2,+12,dup(13)(q22q31)x2, 
der(14)t(14;19)(p11;q13),add(15)(q15)x2, 
der(17)t(11;17)(q12;q22),+19,der(19)t(15;19) 
(q21;q13)x2,+20 [cp25]
rev ish dim(X)(p),dim(X)(q22q28),dim(1)(p34p36), 
enh(1)(p33q44),enh(2)(p25q14),dim(2)(q21q37), 
amp(3)(p22p26),dim(3)(p14p21),dim(3)(q13q28), 
dim(4),amp(5)(p),dim(5)(q13q14),enh(5)(q22q35), 
amp(5)(q23q35),dim(6)(p21p25),dim(6)(q21q27), 
amp(7),amp(8),dim(9),enh(10),enh(11),amp(11)(p), 
enh(12)(p13q23),dim(13)(q12q21),enh(13)(q22q31), 
dim(13)(q32q34),enh(14)(q21q32),dim(15)(q),dim(16), 
dim(17)(p),enh(17)(q21q24),amp(17)(q21q22),dim(18),enh(19)(p
12q13),amp(19)(q13),dim(20)(p12p13), 
enh(20)(q12q13),dim(21)(q),dim(22)(q)
C643 72~82,YY,add(X)(p?),der(X)add(X)(q?)add(X)(p?), 
der(1)t(1;5)(p36;q13),der(1;4)(p10;q10),+del(1)(q10), -
2,add(2)(q11),+der(9;11)(q10;q10),add(4)(p15), 
+i(5)(p10),der(8;15)(q10;q10)x2,+der(8;13) 
(q10;q10),-9,-10,add(10)(q25),-11,dic(11;11)dup(11) 
(pter→q13::q23→q14::q14→q23::p15),der(?)t(?;6) 
(?;q15),mar1,mar2,mar3 [cp25]
rev ish enh(X)(p22),dim(X)(p11p21),enh(X)(q21q28), 
enh(1)(p),amp(1)(p11p31),enh(2)(p11p22),dim(2)(q), 
enh(3)(q),dim(4)(p15p16),enh(5)(p),enh(5)(q14q35), 
amp(5)(q21q33),enh(6)(p12q27),dim(8)(p21p23), 
enh(8)(q),amp(8)(q11q23),dim(10)(p14p15), 
dim(10)(q),enh(11)(p),dim(11)(q13q25),enh(12) 
(p12p13),dim(12)(q22q24),dim(13)(q),enh(14)(q), 
dim(15)(q),enh(16)(q),dim(17)(p12p13),dim(17) 
(q11q21),dim(18)(q12q23),enh(20)(p11q13),dim(21)(q)
8505C 59~63,X,-X,der(X)t(X;9)(p22;q13),-1,del(1)(q12), 
del(1)(p11),-2,der(3)del(p14)del(q27),-4,+i(5)(p10), -
7,i(8)(q10),del(9)(p21),-10, del(12)(q15),-13,-14,-18, -
19,+20,+20,-21,-22,+mar [cp25]
rev ish dim(X),dim(1)(p13p32),dim(1)(q22q43),dim(2), 
dim(3)(p12p24),enh(3)(q),dim(4),amp(5)(p),enh(5)(q), 
enh(6),dim(7)(p13p21),dim(7)(q11q35),dim(8) 
(p12p23),amp(8)(q),dim(9)(p23p24),enh(9)(p13q34), 
dim(10)(p15q25),enh(11),dim(13)(q),enh(14)(q12q32), 
enh(15)(q),enh(16)(q11q21),enh(17),dim(18)(q12q22), 
amp(20),enh(21)(q22),dim(22)(q12q13)
Karyotype and CGH description follow the guidelines of the ISCN (2005) [6].BMC Cancer 2008, 8:371 http://www.biomedcentral.com/1471-2407/8/371
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7 cell lines, whereas gains at 11p and 17q and losses at 8p,
13q, 18q, and Xp were seen in 4/7 cell lines (Figures 1, 2,
3). Recurrent amplification events were seen at 8q (4 cell
lines), 20q (3 cell lines), and 5p, 5q, 7pq, and 20p (2 cell
lines each, Table 3). Gains at 14q21q32 and losses at
2q21q37 and 4p15p16 were seen exclusively in the three
UTC cell lines (HTH74, C643 and 8505C), whereas none
of the imbalances detected in the three papillary-derived
cell lines (TPC-1, K1 and B-CPAP) was exclusive of that
subset. XTC-1 (follicular Hürthle-cell tumor) shared copy
number imbalances with papillary and/or UTC cell lines,
and so no histotype-related copy number features can be
highlighted.
Karyotype review
A total of 125 abnormal karyotypes from independent
samples of patients with non-medullary thyroid carci-
noma were retrieved from Mitelman's database (25 litera-
ture references). Tumors with papillary differentiation
represented the largest group (n = 75) and encompassed
mostly samples with classical morphology, although at
least 8 tumors were classified as follicular variants of pap-
illary carcinoma. In general, papillary tumors displayed
very simple karyotypes with a modal number of 46 chro-
mosomes per sample, and an average of 2.4 aberrations
per tumor. Whereas few recurrent structural aberrations
were seen, 12 cases displayed rearrangements at 10q11
(RET locus), and indeed seven samples displayed the typ-
ical inv(10)(q11.2q21) generating the RET/PTC1 chi-
mera, two samples displayed the t(7;10)(q35;q21) variant
(RET/PTC6), and the t(1;10)(p13;q11) and
t(10;17)(q11;q23) were seen in one sample each (RET/
PTC7 and RET/PTC2, respectively). Loss of Y (n = 8), loss
of 22 (n = 8) and gain of chromosome 5 (n = 5) and/or 7
(n = 10) were numerical aberrations recurrently observed.
One of the eight papillary tumors with follicular growth
pattern displayed the t(2;3)(q13;p25) associated with fol-
licular tumors.
Within the group of tumors with follicular histotype (n =
42), the modal number of chromosomes per sample was
also 46, but an average of 5.9 aberrations per tumor was
observed. Again few recurrent structural aberrations were
described, and only two samples displayed the
t(2;3)(q13;p25) responsible for the PAX8-PPAR  chimera.
Additional recurrent breakpoints were seen at 1p13 (n =
3) and 7p15 (n = 3). Numerical aberrations were much
more frequent in this subgroup, however, including recur-
Overview of genomic findings in papillary thyroid carcinoma Figure 1
Overview of genomic findings in papillary thyroid carcinoma. Karyotype and CGH copy number information from 
clinical samples reported in the literature (top two charts) and from the three papillary cell lines included in this study (bottom 
charts) are included.BMC Cancer 2008, 8:371 http://www.biomedcentral.com/1471-2407/8/371
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rent gains of chromosome 5 (n = 4), 7 (n = 10), 16 (n = 4)
and 20 (n = 4) and losses of 2 (n = 6), 3 (n = 5), 6 (n = 4),
8 (n = 7), 11 (n = 6), 13 (n = 6), 15 (n = 6), 17 (n = 8), 18
(n = 9), 21 (n = 6) and 22 (n = 4).
Karyotypic information for anaplastic thyroid carcinomas
is more difficult to interpret, as it is limited to 8 samples
displaying very complex and incompletely described kary-
otypes. The median number of chromosomes per sample
was 76, and on average each tumor displayed 16 cytoge-
netic aberrations. Recurrent translocation breakpoints
were seen at 7q11 (n = 3) and 11p15 (n = 3), but no other
structural or numerical aberrations were seen in more
than one sample.
CGH review
Fifteen publications dealing with non-medullary thyroid
carcinoma samples could be mined for DNA copy
number information, providing a total of 270 independ-
ent tumors. Of these, 157 (58%) displayed copy number
changes. Papillary tumors comprised the main group of
samples (n = 158), of which 67 (42%) displayed copy
number aberrations. This group generally displayed few
aberrations per sample, mostly involving small gains and/
or deletions. The distribution of changes across the
genome, however, seems to follow a random pattern, as
the same chromosomes were often lost or gained in simi-
lar proportions in independent studies (Fig. 1). Concern-
ing follicular tumors, 47 out of 58 samples (81%)
displayed copy number changes that were clearly non-ran-
dom. Whole chromosome alterations were particularly
frequent, of which gains of 5, 7 and 12 were the most
common and losses of chromosomal regions at 2q, 6q,
9p, 11q, 13q, and 22q are also noteworthy for its fre-
quency (Fig. 2). Finally, in the subset of anaplastic
tumors, 43 out of 54 samples (80%) displayed copy
number aberrations. These complex tumors showed sev-
eral copy number alterations per sample, affecting almost
all chromosomes. However, a clearly non-random pattern
of alterations can be seen, in which smaller regions of
gains and losses (rather than whole chromosome aberra-
tions) are frequent (Fig. 3). In particular, terminal gains at
1p, 3q, 5p, 7p, 8q and 20q, as well as losses at 5q, 9p, 13q,
18q and Xp, were seen in up to 20% of the samples.
Fluorescence in situ hybridization
FISH data corroborated the findings obtained by G-band-
ing and CGH regarding chromosome 5 markers in cell
lines C643 and HTH74. Whereas considerable variability
was seen in nuclei and metaphases from C643 cells, the
most representative cellular population displayed signals
corresponding to three normal chromosomes five, an
i(5)(p10) and a large isochromosome containing several
5q33-34 segments. In HTH74 cells, and in addition to an
i(5)(p10), the two large chromosome 5 derivatives
showed one extra signal for the CSF1R probe, confirming
that a duplication encompassing this region had occurred.
Discussion
Cell lines are widely used by the scientific community as
cellular models in cancer research, providing unique
opportunities to perform in vivo studies otherwise imprac-
Overview of genomic findings in follicular thyroid carcinoma Figure 2
Overview of genomic findings in follicular thyroid carcinoma. Karyotype and CGH copy number information from 
clinical samples reported in the literature (top two charts) and from the follicular cell line included in this study (bottom charts) 
are included.BMC Cancer 2008, 8:371 http://www.biomedcentral.com/1471-2407/8/371
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ticable in clinical samples. In many cases, however, cell
lines are poorly characterized from a genetic point of view,
reducing their usefulness as tumor models and making
more difficult the recognition of mistaken identities. In
our effort to assess the cytogenetic features of eight com-
monly used human thyroid carcinoma cell lines we came
across two such examples. The first unexpected finding
occurred when the karyotypes of TPC-1 and FB2 were
compared, as several unique cytogenetic abnormalities
were shared by the two cell lines. The second example
involves cell line K1, which shares the complex cytoge-
netic markers of cell line GLAG-66. Our data and the
review of the literature (discussed below) allow us to con-
clude that FB2 derived from TPC-1 through a cell culture
cross-contamination, whereas K1 derived from GLAG-66
likely due to a similar mishap.
Cytogenetic data on TPC-1 is unexpectedly scarce if one
bears in mind that this cell line has been studied for more
than 20 years [10]. It is known to harbor an
inv(10)(q11.2q21) that fuses the RET proto-oncogene at
10q11.2 with the promoter region of the H4  gene
(10q21), creating the RET/PTC1 chimera [11]. Oncogenic
fusion events involving RET occur in a large percentage of
papillary thyroid carcinomas and multiple fusion partners
have been identified [12-14]. A more distinguishing fea-
ture of this diploid cell line, however, is the complex
translocation involving chromosomes 1, 10 and 21 [15].
From a cytogenetic point of view, this t(1;10;21) repre-
sents a unique fingerprint for TPC-1 cells, unequivocally
confirming the authenticity of our sample. The near-tetra-
ploid cell line FB2 was more recently reported by Basolo
et al. (2002), who provide a quinacrine mustard staining
(QFQ banding) karyogram fully compatible with our
findings [16]. Strikingly, two copies of each of the three
abnormal chromosomes resulting from the t(1;10;21) are
readily identifiable in their Figure 4, together with other
structural changes seen in TPC-1, such as a
del(7)(q22q31) and an i(8)(q10). It is likely that Basolo
et al. did not notice the cytogenetic similarities between
these cell lines due to the different ploidy and because
they misinterpreted the der(10)t(1;10;21) as an
inv(10)(q11.2p15.3), which would have a similar mor-
phology under QFQ staining. The authors also state that
both TPC-1 and FB2 cell lines were utilized simultane-
ously in their laboratory and their experimental data on
the two cell lines are identical [16]. Since the karyotypes
we determined for TPC-1 and FB2 are compatible with the
original reports for both cell lines, we must conclude that
a cross-contamination mishap occurred during the
Overview of genomic findings in anaplastic thyroid carcinoma Figure 3
Overview of genomic findings in anaplastic thyroid carcinoma. Karyotype and CGH copy number information from 
clinical samples reported in the literature (top charts) and from the three anaplastic cell lines included in this study (bottom 
charts) are included.BMC Cancer 2008, 8:371 http://www.biomedcentral.com/1471-2407/8/371
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attempt to establish FB2, which in fact represents a tetra-
ploid population of TPC-1 cells.
Another example of misidentity was found when analyz-
ing K1 cells, which display two copies of a very distinctive
chromosome 1 derivative containing several 9p segments
(Additional file 3). Whereas Wyllie et al. were the first to
report the use of K1 cells to characterize several of its
molecular features, no cytogenetic information was pro-
vided [17]. Two years later, the group that supplied Wyllie
and coworkers with the K1 cell line reported its establish-
ment, although again no karyotypic information was
given [18]. Interestingly, this group had reported in 1993
the establishment and cytogenetic characterization of a
novel near-diploid thyroid cell line named GLAG-66, and
the presence of the same unique chromosome 1 derivative
in this cell line is very clear from the karyotypic descrip-
tion and figures provided [19]. From a cytogenetic point
of view, the complexity of this shared rearrangement
clearly confirms that K1 is a tetraploid subpopulation of
the GLAG-66 cell line, which was obtained from a metas-
tasis of a well-differentiated papillary thyroid carcinoma.
Our combined chromosome banding and CGH analysis
of the remaining cell lines allowed a detailed genomic
characterization of their chromosomal changes, and a
very high concordance between the two genome screening
methodologies was achieved. Our data are also compati-
ble with the existing literature findings available for some
of these cell lines, which are scattered across several pub-
lications (Table 1). In particular, CGH had previously
been applied to TPC-1 cells with the same overall findings
[20], even if the lower complexity in that study suggests
that our TPC-1 cells acquired several additional chromo-
some changes in vitro. In accordance, a recent report by
van Staveren et al. (2007) shows a G-banded karyogram of
TPC-1 that is fully compatible with our findings, although
the corresponding karyotypic description was not pro-
vided [21]. Detailed cytogenetic findings on B-CPAP
[22,23] and very recently on the anaplastic cell lines C643,
8505C and HTH74 [24] were also available for compari-
son. The use of M-FISH in these studies allowed a very
refined characterization of several chromosomal markers
of unclear origin that we also observed in our samples. We
took the high-resolution information reported in these
studies into account when generating Table 2. Interest-
ingly, whereas virtually all rearranged chromosomes pre-
viously described for cell lines B-CPAP, 8505C and
HTH74 are easily identifiable in our data, suggesting these
tumor models remain genetically stable in culture, the
C643 cell line showed extensive inter-cellular variability
and our karyotype shows several dissimilarities to the
findings by Lee et al. (2007)[24]. This cell line, derived
from a highly aggressive metastatic tumor, seems to be
genetically unstable and prone to clonal evolution during
culture, thus requiring caution when interpreting and
comparing results.
Upon describing the genomic background it was also
important for us to integrate the findings with known
molecular features of the cell lines and to assess their clin-
ical representativeness as tumor models. The meta-analy-
sis of existing cytogenetic and CGH copy number
information on non-medulary thyroid tumors showed
that papillary carcinomas tend to display simple diploid
karyotypes in which rearrangements at 10q11 (RET locus)
are recurrent events, even if no specific copy number
changes could be associated with this histotype (Figure 1).
Of the three papillary cell lines, TPC-1 is the only one to
harbor a RET rearrangement, whereas K1 (GLAG-66) and
B-CPAP were recently shown to display the V600E BRAF
mutation [25]. Interestingly, K1 (GLAG-66) and B-CPAP
share several copy number changes (Figure 1), whereas
the TPC-1 profile is clearly different from these other two
models. Primary follicular carcinomas also tend to display
a near-diploid set of chromosomes, but are more complex
and display distinctive copy number changes involving
mainly gains and losses of whole chromosomes (Figure
2). A recurrent t(2;3) translocation resulting in the PAX8-
PPAR  chimera can be seen in a subset of samples [26].
The XTC-1 cell line does not harbor this rearrangement,
but the CGH profile follows the non-random pattern of
most follicular tumors [27], with gains at 1q, 5, 7, 12, 16
and 20. No mutations in BRAF or RAS have been observed
in this cell line [25]. At the more aggressive end of the
malignancy spectrum, anaplastic primary carcinomas dis-
Table 3: Overview of recurrent CGH findings in seven thyroid 
carcinoma cell lines
Frequency SRO
Gains
5p 6/7 5p12p15
5q 6/7 5q22q35
8q 6/7 8q11q24
20q 6/7 20q12q13
11p 4/7 11p12p15
17q 4/7 17q21q24
Losses
8p 4/7 8p22p23
13q 4/7 13q12q21
13q32q34
18q 4/7 18q12q22
Xp 4/7 Xp11p21
Amp
8q 4/7 8q11q23
20q 3/7 20q11q13
5p 2/7 5p12p15
5q 2/7 5q23q33
7pq 2/7 7p22q36
20p 2/7 20p11p13
For gains and losses, only regions seen in more than 3 cell lines are 
provided. Abbreviations: SRO, smallest region of overlap; Amp, 
amplifications.BMC Cancer 2008, 8:371 http://www.biomedcentral.com/1471-2407/8/371
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play correspondingly complex karyotypes with near-trip-
loid chromosomal contents and many aberrations per
tumor, even if only few recurrent structural abnormalities
are observed (Figure 3). The three anaplastic cell lines fol-
low this pattern (all display complex profiles with note-
worthy gains/amplifications at 5p, 8q and 20q), with no
detectable rearrangements of RET or PAX8. Interestingly,
cell line 8505C displays a V600E mutation in BRAF,
whereas TP53 mutations can be seen in both C643 and
8505C [25]. It is noteworthy that cell lines 8505C and B-
CPAP, which display a near-triploid karyotype with losses
at chromosomal region 7q by CGH, show a homozygous
pattern for the V600E BRAF mutation (BRAF is mapped to
7q34). This indicates that the two cytogenetically normal
chromosomes 7 observed in both cell lines carry the
mutation. Rather than resulting from two independent
mutational events, this finding suggests that the BRAF
mutation occurred in one chromosome 7 that later was
duplicated and that the 7q with the wild type BRAF was
deleted.
Unfortunately, other candidate genes are difficult to high-
light in this panel of cell lines, as regions recurrently
affected by copy number gains and/or losses always
involved large DNA segments. It should also be noted that
continued cell culture tends to generate clonal evolution
in vitro, and in particular the tetraploidization phenom-
ena seems to occur frequently in cell lines over time (FB2
and K1 being good examples). Even if these events may
generate considerable karyotypic differences in cell line
stocks in different laboratories, one would expect that the
biologically relevant oncogenic rearrangements character-
izing each cell line are maintained in the different sub-
populations. Classical cytogenetic analysis will efficiently
detect such clonal divergence, although it requires consid-
erable time and expertise. An alternative and less time-
consuming method to ensure cell line identity is genotype
analysis using Short Tandem Repeat (STR) markers
[24,25], although clonal evolution will not be detected
using this approach. Indeed, a recently published survey
of 40 presumptive thyroid cell lines using STR markers
showed that only 23 cell lines displayed unique profiles
consistent with thyroid origin (encompassing the seven
unique cell lines in the current study), with the remaining
cell lines being derivatives or cross-contaminants from
different origins, such as melanoma and colon cancer cell
lines [28].
Conclusion
We report the genetic background of seven independent
thyroid cell lines of papillary, follicular or anaplastic ori-
gin, highlighting distinctive chromosomal markers as well
as common genomic regions of interest for future studies.
Importantly, the literature review indicates these cellular
models display genetic alterations representative of those
found in clinical tumors of the correspondent histotype.
Our findings further remind us that cell line contamina-
tion happens more frequently than one would like to
admit, and that karyotyping and/or genotyping are effi-
cient methods for clonal analysis and determination of
cell line identity. We therefore recommend that karyotype
and genotype analysis be performed from early passages
and on a regular basis in every laboratory working with
cancer cell lines to help interpret the genetic data, to detect
in vitro clonal evolution with time, and to ensure cell line
authenticity.
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